List of Excipients in Branded Drug NADOLOL

Generic Drugs Containing NADOLOL

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	nadolol	0378-0028	ANHYDROUS LACTOSE
Mylan Pharmaceuticals Inc	nadolol	0378-0028	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	nadolol	0378-0028	CROSCARMELLOSE SODIUM
Mylan Pharmaceuticals Inc	nadolol	0378-0028	D&C YELLOW NO. 10
Mylan Pharmaceuticals Inc	nadolol	0378-0028	MAGNESIUM STEARATE
Mylan Pharmaceuticals Inc	nadolol	0378-0028	SODIUM LAURYL SULFATE
Sandoz Inc	nadolol	0781-8004	CELLULOSE, MICROCRYSTALLINE

What are the Most Frequently-Used Excipients in NADOLOL?

# Of NDCs	Excipient
1	ALUMINUM OXIDE
11	ANHYDROUS CITRIC ACID
4	ANHYDROUS LACTOSE
43	CELLULOSE, MICROCRYSTALLINE
13	CITRIC ACID MONOHYDRATE
4	COPOVIDONE
4	COPOVIDONE K25-31

Nadolol Excipient Strategy and Commercial Opportunities

Last updated: August 10, 2026

Nadolol is a mature, genericized beta-adrenergic blocker with limited active-ingredient patent protection and low conventional tablet differentiation. The strongest commercial opportunities are in excipient-enabled products: lactose-free tablets, improved dissolution, pediatric and geriatric liquids, adherence-oriented dose formats, and clinically supported compounded or ready-to-use suspensions.

Nadolol is marketed primarily as an immediate-release oral tablet in 20 mg, 40 mg, 80 mg and 160 mg strengths. It is a nonselective beta blocker used for hypertension, angina and certain tachyarrhythmias. The drug has low aqueous solubility, is administered once daily, and is eliminated largely through the kidneys. These characteristics make dissolution control, dose flexibility and renal-use labeling more important than extended-release technology.[1,2]

What is the current FDA and Orange Book status of nadolol?

Nadolol is an established immediate-release prescription drug with generic competition in the United States. The reference product is Corgard, associated with NDA 018063. FDA records identify Corgard as discontinued from marketing rather than withdrawn for safety or effectiveness reasons.[3]

Regulatory item	Nadolol status
Reference product	Corgard
Active ingredient	Nadolol
Dosage form	Immediate-release tablet
Common strengths	20 mg, 40 mg, 80 mg, 160 mg
FDA product type	Small-molecule drug
Generic pathway	ANDA, subject to abbreviated approval requirements
Biologic status	Not applicable
Biosimilar pathway	Not applicable
Primary US exclusivity issue	Generic substitution and formulation differentiation, not biologic interchangeability
Orange Book relevance	Reference-product and therapeutic-equivalence information; patent listings must be checked against the current FDA edition
Reference product marketing	Corgard is listed as discontinued from marketing in FDA records

The key commercial distinction is that nadolol does not create a biosimilar risk profile. It is a conventional small molecule. Competition comes from ANDA-approved tablets, authorized or private-label generics, pharmacy compounding and potentially 505(b)(2) products with a new dosage form or delivery system.

When does nadolol lose exclusivity?

Nadolol's original compound and product exclusivity are long expired. The historical Corgard approval dates to the early 1980s, placing the product well beyond the ordinary 20-year patent term for the original product concept.[3,4]

No commercially material branded exclusivity remains for the conventional nadolol tablet. The relevant barriers are:

• ANDA approval and manufacturing compliance.
• Demonstration of pharmaceutical equivalence and bioequivalence.
• Product-specific formulation or manufacturing patents, if any remain enforceable.
• State pharmacy-compounding requirements.
• Commercial access to active pharmaceutical ingredient.
• Supply reliability for low-volume strengths.

Are there active nadolol patents?

The original nadolol composition and conventional oral tablet concepts are too old to provide meaningful current exclusivity. Any live patent risk would more likely arise from a later formulation, pediatric liquid, taste-masked system, particle-size process, co-processed excipient system or other delivery technology.

A patent search should distinguish between:

1. Expired composition-of-matter patents.
2. Expired Corgard formulation patents.
3. Abandoned or expired continuation applications.
4. Third-party patents covering liquid vehicles, taste masking or manufacturing processes.
5. Current patents that claim a specific excipient combination rather than nadolol itself.

The FDA Orange Book should be checked for current listed patents associated with the relevant reference or approved product. FDA approval records alone do not establish freedom to operate for every formulation or manufacturing process.[4]

What excipients are used in nadolol tablets?

Nadolol tablets generally use conventional direct-compression or wet-granulation excipients. Exact compositions vary by manufacturer and strength. FDA labeling and DailyMed entries should be used for product-specific inactive-ingredient confirmation because generic formulations are not identical.[1,5]

Typical excipient classes include:

Excipient class	Commercial function	Nadolol relevance
Diluent	Provides tablet mass and compressibility	Important because nadolol doses range from 20 mg to 160 mg
Microcrystalline cellulose	Compression, disintegration and structural support	Supports robust immediate-release tablets
Lactose or another soluble filler	Bulking and mouthfeel	Creates an opportunity for lactose-free positioning
Pregelatinized starch or starch	Binder and disintegrant	Can improve tablet breakup
Povidone or related binder	Granule strength	Useful when high-dose tablets require mechanical robustness
Crospovidone or croscarmellose sodium	Rapid disintegration	Relevant to dissolution of a poorly water-soluble drug
Magnesium stearate	Lubrication	Must be controlled because over-lubrication can slow wetting and dissolution
Colloidal silicon dioxide	Flow and moisture management	Supports high-speed compression and blend uniformity
Film-coating polymers	Identification, protection and swallowability	Useful for sensory differentiation and handling

Nadolol is described as slightly soluble in water. For an immediate-release product, the formulation objective is not simply tablet breakup. It is rapid wetting, dispersion and reproducible dissolution across the product's shelf life.[1]

How should an excipient strategy address nadolol's solubility?

The central technical issue is dissolution performance. Nadolol does not require a complex controlled-release system for its primary once-daily use, but its formulation must avoid excipient combinations that produce slow wetting or excessive hydrophobicity.

Recommended formulation priorities

A commercially defensible formulation program should evaluate:

1. Particle-size control. Smaller and more uniform nadolol particles can improve dissolution, although the effect depends on agglomeration and surface properties.
2. Disintegrant optimization. Crospovidone, croscarmellose sodium or starch-based systems can be screened for rapid tablet breakup.
3. Lubricant control. Magnesium stearate concentration and blending time should be optimized to prevent dissolution retardation.
4. Wetting enhancement. A permitted surfactant or hydrophilic excipient may improve dispersion, but the benefit must be balanced against stability, taste and regulatory complexity.
5. Granulation selection. Wet granulation can improve content uniformity and mechanical strength but introduces moisture and drying variables. Direct compression can reduce process steps if powder flow and segregation are controlled.
6. Packaging protection. Moisture-barrier packaging may be important where the chosen excipient system is hygroscopic or where dissolution changes during storage.

A strong formulation should show equivalent or superior dissolution across relevant pH conditions, acceptable impurity growth, adequate tablet hardness and rapid disintegration. A novel excipient system has commercial value only if it produces a measurable performance advantage over standard generic tablets.

What formulations are protected by nadolol excipient patents?

Potentially protectable formulation categories include:

• Nadolol immediate-release tablets with a defined particle-size distribution.
• Tablets containing a specified disintegrant-to-drug ratio.
• Lactose-free or sugar-free formulations with improved dissolution.
• Taste-masked oral suspensions.
• Ready-to-use pediatric solutions or suspensions.
• Pharmaceutical compositions with enhanced stability in aqueous vehicles.
• Coated tablets designed to reduce bitterness during swallowing.
• Unit-dose liquid products with defined preservatives and pH ranges.
• Amorphous or solid-dispersion formulations, if they deliver a demonstrated bioavailability or dissolution benefit.

The patent case is stronger when claims tie the excipient system to a measurable technical result, such as a dissolution profile, stability threshold, reduced dose variability or improved palatability. A claim that merely substitutes one conventional filler for another is vulnerable to obviousness challenges.

Can an excipient patent block generic nadolol?

Usually, no broad blocking position should be expected from a conventional excipient patent. A narrow formulation patent may constrain a specific product design, but generic manufacturers can often avoid it by selecting another filler, binder, lubricant or disintegrant.

The most defensible patent strategy would combine:

• Composition claims.
• Manufacturing-process claims.
• Dissolution or stability limitations.
• Liquid-product claims.
• Device or unit-dose packaging claims where applicable.

A patent owner should also consider whether the product can be approved through an ANDA, a 505(b)(2) application or a state-level compounding route. The regulatory pathway affects both claim scope and litigation exposure.

What commercial opportunities exist for nadolol excipients?

1. Lactose-free and excipient-reduced tablets

Many established generic tablets use inexpensive conventional fillers. A lactose-free formulation could target patients with lactose intolerance, excipient sensitivity or dietary preferences. The commercial opportunity is limited by the low price of generic nadolol, but a differentiated product could obtain pharmacy, hospital or specialty-distributor placement.

The formulation should avoid creating a new problem through excessive tablet size, poor hardness or slower dissolution. Mannitol, microcrystalline cellulose, dibasic calcium phosphate or other fillers may be evaluated, subject to compatibility and product-specific performance.

2. Pediatric oral suspension

Nadolol is used in pediatric cardiology, including management of selected arrhythmia and long-QT settings under specialist supervision. Pediatric patients may require weight-based dosing that is difficult to achieve with 20 mg tablets. A validated liquid suspension could improve dose flexibility and reduce reliance on extemporaneous pharmacy preparation.

The commercial product would need:

• Uniform dose delivery after shaking.
• A clinically useful concentration.
• Acceptable sedimentation and redispersibility.
• Preservative effectiveness where needed.
• Microbial and chemical stability.
• Palatable flavor and manageable viscosity.
• An oral syringe compatible with the concentration.
• Clear renal-dosing instructions.

A ready-to-use suspension may have more value than another conventional tablet because it solves a practical administration problem.

3. Taste-masked liquid

Nadolol liquids can encounter bitterness and aftertaste. Taste masking may use polymeric coating, ion exchange, complexation, flavor systems or a suspension vehicle. The best approach depends on whether the product is a true solution or a suspension.

A taste-masked suspension is generally easier to design than a fully solubilized liquid when the active ingredient has limited water solubility. A suspension can also offer higher dose flexibility, but it introduces sedimentation, redispersibility and dose-uniformity requirements.

4. Geriatric and dysphagia-oriented tablets

Nadolol is commonly used in older adults, who may have swallowing difficulty and polypharmacy-related adherence problems. Opportunities include:

• Smaller tablets at lower strengths.
• Film coatings with improved swallowability.
• Orally dispersible tablets.
• Scored tablets, if dose-splitting performance is demonstrated.
• Tablets with reduced friability and clearer strength differentiation.

An orally disintegrating tablet would need to address nadolol's taste, low solubility and dose size. It could be commercially attractive, but the development burden would exceed that of a standard generic tablet.

5. Hospital and specialty pharmacy packaging

Unit-dose blister packaging, calendar packs and moisture-protective packaging may support institutional use and adherence. The value is operational rather than pharmacological. Packaging patents may provide limited differentiation, but regulatory and manufacturing execution are likely to matter more than exclusivity.

How does nadolol compare with other beta blockers?

Nadolol competes with propranolol, atenolol, metoprolol and carvedilol. Each has a different formulation and excipient opportunity profile.

Drug	Primary formulation profile	Excipient opportunity relative to nadolol
Nadolol	Immediate-release tablet; low water solubility; once daily	Pediatric suspension, dissolution improvement and dysphagia formats
Propranolol	Immediate-release and extended-release products; extensive liquid use	Less white space in pediatric liquid delivery
Atenolol	Immediate-release tablets; generally simple generic formulations	Similar lactose-free and liquid opportunities
Metoprolol	Immediate-release and extended-release products	More complex release-control and multiparticulate competition
Carvedilol	Immediate-release and controlled-release products	Greater formulation complexity and more differentiated dosage forms

Nadolol's commercial white space is narrower than for drugs with active extended-release markets. Its advantage is that a liquid or administration-focused product can address a specific clinical need without competing directly with an established complex-release platform.

What regulatory pathway applies to a new nadolol formulation?

A conventional tablet that is pharmaceutically equivalent and bioequivalent to an approved reference product can generally use the ANDA pathway. A materially different dosage form, concentration, route, clinical use or formulation may require a 505(b)(2) application.[6]

ANDA considerations

An ANDA candidate must address:

• Active ingredient identity and strength.
• Dosage-form equivalence.
• Dissolution and bioequivalence.
• Inactive-ingredient safety.
• Manufacturing controls.
• Stability and container closure.
• Labeling requirements.
• Orange Book patent certifications.

A different excipient system is permissible if it does not affect safety, efficacy, bioequivalence or product quality.

505(b)(2) considerations

A 505(b)(2) strategy may be appropriate for:

• A new pediatric liquid concentration.
• An orally disintegrating product.
• A new dosage form.
• A formulation with a clinically relevant administration advantage.
• A ready-to-use product replacing pharmacy compounding.

The commercial case must justify the added regulatory cost. A simple generic tablet with a different filler is unlikely to support a strong 505(b)(2) premium.

What Paragraph IV and litigation risks affect nadolol?

Paragraph IV risk is limited for the original nadolol molecule because the foundational patent term has expired. The principal litigation risk would arise if a new formulation patent is listed in the Orange Book or asserted against an ANDA applicant.

Potential disputes may involve:

• Whether a listed patent properly claims the approved product.
• Obviousness of the excipient combination.
• Written description and enablement.
• Infringement by a generic's inactive-ingredient system.
• Patent-term expiration calculations.
• Whether a 505(b)(2) applicant can carve out a patented use.

No current high-value nadolol litigation position should be assumed from the existence of a formulation patent. The practical strength of the estate depends on claim breadth, validity, product detectability and the ease of designing around the claims.

What manufacturing and geographic barriers exist?

Nadolol is a mature active ingredient with manufacturing processes that are likely available from multiple qualified suppliers. The main barriers are therefore execution and quality rather than basic chemical access.

Relevant barriers include:

• API particle-size consistency.
• Residual-solvent and impurity control.
• Blend uniformity for low-dose tablets.
• Segregation across multiple strengths.
• Dissolution reproducibility.
• Moisture sensitivity of the selected excipient system.
• Qualification of alternate API suppliers.
• Regulatory filings for manufacturing-site changes.
• Supply continuity for specialty excipients and packaging.

Geographic opportunities are strongest where pediatric liquid access, hospital supply or local pharmacy compounding creates a product gap. The United States offers the clearest ANDA and 505(b)(2) frameworks. European and other markets require separate assessment of national reference products, mutual-recognition strategy, pediatric requirements and local substitution rules.

What is the commercial outlook for nadolol excipient innovation?

The conventional tablet market is price-sensitive and crowded. A new excipient strategy is commercially viable when it targets a defined use case with limited direct competition.

Opportunity	Technical complexity	Differentiation	Commercial outlook
Standard lactose-free tablet	Low to moderate	Low	Moderate in institutional and specialty channels
Improved-dissolution tablet	Moderate	Moderate	Moderate if supported by robust data
Pediatric suspension	Moderate to high	High	Strongest specialty opportunity
Taste-masked liquid	High	High	Attractive if palatability is demonstrated
Orally disintegrating tablet	High	Moderate to high	Selective opportunity
Extended-release nadolol	High	Uncertain	Weak unless a clear clinical advantage exists
Unit-dose packaging	Low	Low	Limited stand-alone value
Novel solid dispersion	High	Potentially high	High scientific risk and regulatory burden

Revenue exposure from nadolol alone is unlikely to support a large platform investment unless the formulation technology can be reused across other poorly soluble cardiovascular drugs. The most attractive strategy is a focused specialty product, particularly a pediatric liquid or a formulation designed for patients who cannot swallow tablets.

Key Takeaways

• Nadolol is a mature small-molecule drug with expired foundational exclusivity and established generic competition.
• Conventional tablet differentiation is difficult because price is low and standard excipients are widely available.
• Dissolution, taste, dose flexibility and swallowability are the main formulation targets.
• A pediatric ready-to-use suspension is the strongest identifiable excipient-led opportunity.
• Lactose-free tablets and geriatric-friendly dosage forms offer lower-risk but narrower differentiation.
• Broad patent protection for routine excipient substitutions is unlikely.
• A defensible formulation estate should combine composition, process, dissolution, stability and liquid-product claims.
• ANDA is appropriate for a conventional bioequivalent tablet; a materially different liquid or dosage form may require a 505(b)(2) strategy.
• Biosimilar risk does not apply. Generic substitution and formulation design-around risk do.
• The commercial case improves if the excipient platform can be reused across other low-solubility cardiovascular drugs.

FAQs About Nadolol Excipient Commercialization

Is nadolol available as a liquid?

Nadolol is primarily marketed as an oral tablet. Liquid preparations may be compounded by pharmacies or developed as specialty formulations, but product-specific availability and stability depend on the formulation and jurisdiction.

Can nadolol be formulated as an orally disintegrating tablet?

Yes, but taste masking, dose loading, tablet strength, dissolution and mechanical robustness must be solved together. The opportunity is technically feasible but more complex than a standard immediate-release tablet.

Does nadolol require a controlled-release formulation?

Not for its established once-daily tablet use. A controlled-release product would need a clear clinical or adherence benefit to justify its development and regulatory burden.

Which excipients are most important for nadolol dissolution?

Disintegrants, wetting agents, particle-size modifiers, hydrophilic fillers and lubricant levels are key variables. Excessive hydrophobic lubrication or poor wetting can impair dissolution.

Is a nadolol pediatric product patentable?

A pediatric product may support patent claims if it has a novel composition, concentration, taste-masking system, stability profile, delivery method or manufacturing process. A routine liquid vehicle alone may provide weak patent protection.

References

1. DailyMed. (n.d.). Nadolol tablet: Prescribing information and inactive ingredients. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. National Center for Biotechnology Information. (n.d.). Nadolol. PubChem compound summary. https://pubchem.ncbi.nlm.nih.gov/compound/Nadolol

3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Corgard, NDA 018063. https://www.accessdata.fda.gov/scripts/cder/daf/

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

5. U.S. National Library of Medicine. (n.d.). DailyMed drug labels. https://dailymed.nlm.nih.gov/dailymed/

6. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2). https://www.fda.gov/drugs/development-resources/505b2-application-process】【。